Research programme: hepatitis C therapeutics - Medivir

Drug Profile

Research programme: hepatitis C therapeutics - Medivir

Alternative Names: ASC-21; MIV-802; Nucleotide polymerase inhibitors - Medivir AB

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleotidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Sweden
  • 18 Aug 2017 MIV 802 licensed to Ascletis in China, Hong Kong, Taiwan and Macau
  • 28 Apr 2017 MIV 802 licensed to Trek Therapeutics worldwide, excluding China, Hong Kong, Taiwan and Macau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top